Autores: Giulia Gall delgado de souza, Bruno Cosme, José Mauro Granjeiro, Fernanda Leve
Resumo: The ddPCR is an absolute DNA quantification technology, allowing the identification of rare mutations, however its application in oncology diagnosis requires evaluation of performance parameters. We performed a qualitative validation of ddPCR, producing and using an in-house standard of DNA containing mutations in EGFR (p.L858R) and KRAS (p.G13D), highly incident in lung and colon cancer, respectively. We analyzed the limit of blank (LOB, < 2 copies/uL), limit of detection (LOD, 10 copies/uL), selectivity and robustness. Our results show that the ddPCR is a robust and specific method, however the commutativity study is still needed.
Download do Artigo